Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 2
1990 1
1991 2
1993 2
1995 3
1996 3
1997 6
1998 9
1999 13
2000 17
2001 12
2002 14
2003 15
2004 8
2005 18
2006 10
2007 8
2008 11
2009 18
2010 27
2011 27
2012 29
2013 31
2014 19
2015 17
2016 17
2017 14
2018 16
2019 20
2020 25
2021 16
2022 17
2023 12
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

410 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials.
Gevaert P, Omachi TA, Corren J, Mullol J, Han J, Lee SE, Kaufman D, Ligueros-Saylan M, Howard M, Zhu R, Owen R, Wong K, Islam L, Bachert C. Gevaert P, et al. J Allergy Clin Immunol. 2020 Sep;146(3):595-605. doi: 10.1016/j.jaci.2020.05.032. Epub 2020 Jun 7. J Allergy Clin Immunol. 2020. PMID: 32524991 Free article. Clinical Trial.
METHODS: Adults with CRSwNP with inadequate response to intranasal corticosteroids were randomized (1:1) to omalizumab or placebo and intranasal mometasone for 24 weeks. Coprimary end points included change from baseline to week 24 in Nasal Polyp Score (NPS) and Nasal Cong …
METHODS: Adults with CRSwNP with inadequate response to intranasal corticosteroids were randomized (1:1) to omalizumab or placebo and intran …
Effectiveness of Intranasal Mometasone Furoate vs Saline for Sleep-Disordered Breathing in Children: A Randomized Clinical Trial.
Baker A, Grobler A, Davies K, Griffiths A, Hiscock H, Kubba H, Peters RL, Ranganathan S, Rimmer J, Rose E, Rowe K, Simpson CM, Davidson A, Nixon G, Perrett KP. Baker A, et al. JAMA Pediatr. 2023 Mar 1;177(3):240-247. doi: 10.1001/jamapediatrics.2022.5258. JAMA Pediatr. 2023. PMID: 36648937 Free PMC article. Clinical Trial.
Evidence from small clinical trials suggests that intranasal corticosteroids improve SDB as measured by polysomnography; however, the effect on symptoms and quality of life is unclear. OBJECTIVE: To determine whether intranasal mometasone furoate is more effective t …
Evidence from small clinical trials suggests that intranasal corticosteroids improve SDB as measured by polysomnography; however, the effect …
Effect of an Intranasal Corticosteroid on Quality of Life and Local Microbiome in Young Children With Chronic Rhinosinusitis: A Randomized Clinical Trial.
Latek M, Lacwik P, Molinska K, Blauz A, Lach J, Rychlik B, Strapagiel D, Majak J, Molinska J, Czech D, Seweryn M, Kuna P, Palczynski C, Majak P. Latek M, et al. JAMA Pediatr. 2023 Apr 1;177(4):345-352. doi: 10.1001/jamapediatrics.2022.6172. JAMA Pediatr. 2023. PMID: 36848113 Free PMC article. Clinical Trial.
INTERVENTIONS: Patients were randomized to receive intranasal mometasone in an atomizer for 12 weeks (1 application per nostril, once per day) and supplemental 3-mL sodium chloride (NaCl), 0.9%, solution in a nasal nebulizer once a day for 12 weeks (INC group) or 3-mL NaCl …
INTERVENTIONS: Patients were randomized to receive intranasal mometasone in an atomizer for 12 weeks (1 application per nostril, once …
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, Pirozzi G, Sutherland ER, Evans RR, Joish VN, Eckert L, Graham NM, Stahl N, Yancopoulos GD, Louis-Tisserand M, Teper A. Wenzel S, et al. Lancet. 2016 Jul 2;388(10039):31-44. doi: 10.1016/S0140-6736(16)30307-5. Epub 2016 Apr 27. Lancet. 2016. PMID: 27130691 Clinical Trial.
Comparative clinical pharmacology of mometasone furoate, fluticasone propionate and fluticasone furoate.
Daley-Yates PT, Deans A, Mehta R, Sousa AR. Daley-Yates PT, et al. Pulm Pharmacol Ther. 2022 Dec;77:102171. doi: 10.1016/j.pupt.2022.102171. Epub 2022 Oct 13. Pulm Pharmacol Ther. 2022. PMID: 36243386 Clinical Trial.
AIMS: To investigate the pharmacokinetics and effects on the hypothalamic-pituitary-adrenal (HPA) axis of mometasone furoate (MF), fluticasone propionate (FP) and fluticasone furoate (FF). ...In each study, 24-h serial blood samples were collected and assayed …
AIMS: To investigate the pharmacokinetics and effects on the hypothalamic-pituitary-adrenal (HPA) axis of mometasone furoate ( …
Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study.
Kerstjens HAM, Maspero J, Chapman KR, van Zyl-Smit RN, Hosoe M, Tanase AM, Lavecchia C, Pethe A, Shu X, D'Andrea P; IRIDIUM trial investigators. Kerstjens HAM, et al. Lancet Respir Med. 2020 Oct;8(10):1000-1012. doi: 10.1016/S2213-2600(20)30190-9. Epub 2020 Jul 9. Lancet Respir Med. 2020. PMID: 32653074 Clinical Trial.
The aim of the IRIDIUM study was to assess the efficacy and safety of a once-daily, single-inhaler combination of mometasone furoate, indacaterol acetate, and glycopyrronium bromide (MF-IND-GLY) versus ICS-LABA in patients with inadequately controlled asthma. ...
The aim of the IRIDIUM study was to assess the efficacy and safety of a once-daily, single-inhaler combination of mometasone furoa …
Mometasone or Tiotropium in Mild Asthma with a Low Sputum Eosinophil Level.
Lazarus SC, Krishnan JA, King TS, Lang JE, Blake KV, Covar R, Lugogo N, Wenzel S, Chinchilli VM, Mauger DT, Dyer AM, Boushey HA, Fahy JV, Woodruff PG, Bacharier LB, Cabana MD, Cardet JC, Castro M, Chmiel J, Denlinger L, DiMango E, Fitzpatrick AM, Gentile D, Hastie A, Holguin F, Israel E, Jackson D, Kraft M, LaForce C, Lemanske RF Jr, Martinez FD, Moore W, Morgan WJ, Moy JN, Myers R, Peters SP, Phipatanakul W, Pongracic JA, Que L, Ross K, Smith L, Szefler SJ, Wechsler ME, Sorkness CA; National Heart, Lung, and Blood Institute AsthmaNet. Lazarus SC, et al. N Engl J Med. 2019 May 23;380(21):2009-2019. doi: 10.1056/NEJMoa1814917. Epub 2019 May 19. N Engl J Med. 2019. PMID: 31112384 Free PMC article. Clinical Trial.
However, there was no significant difference in the response to mometasone or tiotropium, as compared with placebo. Among the patients with a low eosinophil level who had a differential treatment response, 57% (95% confidence interval [CI], 48 to 66) had a better response …
However, there was no significant difference in the response to mometasone or tiotropium, as compared with placebo. Among the patient …
Efficacy and safety of GSP301 nasal spray in children aged 6 to 11 years with seasonal allergic rhinitis.
Prenner BM, Amar NJ, Hampel FC Jr, Caracta CF, Wu W. Prenner BM, et al. Ann Allergy Asthma Immunol. 2022 Nov;129(5):618-626.e2. doi: 10.1016/j.anai.2022.07.029. Epub 2022 Aug 1. Ann Allergy Asthma Immunol. 2022. PMID: 35926824 Free article. Clinical Trial.
BACKGROUND: GSP301 nasal spray is a fixed-dose combination of the antihistamine olopatadine hydrochloride and the corticosteroid mometasone furoate. OBJECTIVE: To evaluate the efficacy, safety, and tolerability of GSP301 in pediatric patients (aged 6 to <12 y …
BACKGROUND: GSP301 nasal spray is a fixed-dose combination of the antihistamine olopatadine hydrochloride and the corticosteroid mometaso …
Efficacy and safety of twice-daily and once-daily olopatadine-mometasone combination nasal spray for seasonal allergic rhinitis.
Andrews CP, Mohar D, Salhi Y, Tantry SK. Andrews CP, et al. Ann Allergy Asthma Immunol. 2020 Feb;124(2):171-178.e2. doi: 10.1016/j.anai.2019.11.007. Epub 2019 Nov 15. Ann Allergy Asthma Immunol. 2020. PMID: 31734334 Free article. Clinical Trial.
BACKGROUND: GSP301 is an investigational fixed-dose combination nasal spray of olopatadine hydrochloride (antihistamine) and mometasone furoate (corticosteroid). OBJECTIVE: To evaluate efficacy and safety of GSP301 in patients with seasonal AR (SAR). METHODS: In thi …
BACKGROUND: GSP301 is an investigational fixed-dose combination nasal spray of olopatadine hydrochloride (antihistamine) and mometasone …
Evaluation of the effects of montelukast, mometasone furoate, and combined therapyon adenoid size: a randomized, prospective, clinical trial with objective data.
Tuhanıoğlu B, Erkan SO. Tuhanıoğlu B, et al. Turk J Med Sci. 2017 Dec 19;47(6):1736-1743. doi: 10.3906/sag-1701-179. Turk J Med Sci. 2017. PMID: 29306232 Free article. Clinical Trial.
The patients were randomized into 4 separate groups, with 30 in each group. Group 1 received 100 mug of mometasone furoate per day, group 2 received 4/5 mg (for age) montelukast per day, and group 3 received mometasone furoate + montelukast. ...There w …
The patients were randomized into 4 separate groups, with 30 in each group. Group 1 received 100 mug of mometasone furoate per …
410 results